Literature DB >> 23849749

Pulmonary embolism in a stroke patient after systemic thrombolysis: clinical decisions and literature review.

Fabio Pilato1, Rosalinda Calandrelli, Paolo Profice, Giacomo Della Marca, Aldobrando Broccolini, Giuseppe Bello, Maria Grazia Bocci, Marisa Distefano, Cesare Colosimo, Paolo Maria Rossini.   

Abstract

Pulmonary embolism can be a catastrophic event that can result in early death or serious hemodynamic dysfunction. The dehydration, immobility, and infections occurring in acute stroke patients puts these patients at risk of developing deep vein thrombosis and pulmonary embolism. Recombinant tissue-type plasminogen activator (rt-PA) is the established therapy for acute ischemic stroke, and its prompt administration results in a better outcome in stroke patients. We describe a 73-year-old man who arrived at the emergency room within 2 hours of acute onset of left hemiparesis who was treated with rt-PA and suffered a pulmonary embolism 3 days after acute stroke therapy. rt-PA is also a current therapy for pulmonary embolism, but an ischemic stroke in the previous 3 months is an absolute contraindication to thrombolysis because of the high risk of intracranial hemorrhage. We discuss clinical and therapeutic decisions and review the current literature.
Copyright © 2013 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute stroke; deep venous thrombosis; heparin; pulmonary embolism; rt-PA; systemic thrombolysis

Mesh:

Substances:

Year:  2013        PMID: 23849749     DOI: 10.1016/j.jstrokecerebrovasdis.2013.06.016

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  1 in total

1.  Incidence and Risk Factors of Lower-Extremity Deep Vein Thrombosis After Thrombolysis Among Patients with Acute Ischemic Stroke.

Authors:  Chunping Ni; Xiuli Yan; Zhuo Liu; Dandan Liu; Zhen-Ni Guo; Hang Jin; Tong Sun
Journal:  Pharmgenomics Pers Med       Date:  2021-09-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.